Contents

List of Contributors *XVII*
Preface *XXI*
A Personal Foreword *XXIII*

Part One Introduction *1*

1 Metabolism in Drug Development *3*
Bernard Testa
1.1 What? An Introduction *3*
1.2 Why? Metabolism in Drug Development *4*
1.2.1 The Pharmacological Context *4*
1.2.2 Consequences of Drug Metabolism on Activity *6*
1.2.3 Adverse Consequences of Drug Metabolism *7*
1.2.4 Impact of Metabolism on Absorption, Distribution, and Excretion *10*
1.3 How? From Experimental Results to Databases to Expert Software Packages *11*
1.3.1 The Many Factors Influencing Drug Metabolism *11*
1.3.2 Acquiring and Interpreting Experimental Results *13*
1.3.3 Expert Software Tools and Their Domains of Applicability *14*
1.3.4 Roads to Progress *16*
1.4 Who? Human Intelligence as a Conclusion *17*
References *19*

Part Two Software, Web Servers and Data Resources to Study Metabolism *27*

2 Software for Metabolism Prediction *29*
Lu Tan and Johannes Kirchmair
2.1 Introduction *29*
2.2 Ligand-Based and Structure-Based Methods for Predicting Metabolism *30*
2.3 Software for Predicting Sites of Metabolism *38*

2.3.1 Knowledge-Based Systems *38*
2.3.2 Molecular Interaction Fields *39*
2.3.3 Docking *39*
2.3.4 Reactivity Models *40*
2.3.5 Data Mining and Machine Learning Approaches *41*
2.3.6 Shape-Focused Approaches *42*
2.4 Software for Predicting Metabolites *43*
2.4.1 Knowledge-Based Systems *44*
2.4.2 Data Mining and Machine Learning Approaches *46*
2.4.3 Molecular Interaction Fields *46*
2.5 Software for Predicting Interactions of Small Molecules with Metabolizing Enzymes *46*
2.6 Conclusions *48*
References *49*

3 Online Databases and Web Servers for Drug Metabolism Research *53*
David S. Wishart
3.1 Introduction *53*
3.2 Online Drug Metabolism Databases *54*
3.2.1 DrugBank *57*
3.2.2 HMDB *59*
3.2.3 PharmGKB *59*
3.2.4 Wikipedia *60*
3.2.5 PubChem *61*
3.2.6 Synoptic Databases: ChEBI, ChEMBL, KEGG, and BindingDB *61*
3.2.7 Specialized Databases: UM-BBD, SuperCYP, PKKB, and PK/DB *63*
3.2.8 Online Database Summary *64*
3.3 Online Drug Metabolism Prediction Servers *65*
3.3.1 Metabolite Predictors *66*
3.3.2 SoM Predictors *66*
3.3.3 Specialized Predictors *68*
3.3.4 ADMET Predictors *70*
3.3.5 Web Server Summary *71*
References *71*

Part Three Computational Approaches to Study Cytochrome P450 Enzymes *75*

4 Structure and Dynamics of Human Drug-Metabolizing Cytochrome P450 Enzymes *77*
Ghulam Mustafa, Xiaofeng Yu, and Rebecca C. Wade
4.1 Introduction *77*
4.2 Three-Dimensional Structures of Human CYPs *78*
4.3 Structural Features of CYPs *78*

4.3.1 CYP-Electron Transfer Protein Interactions *81*
4.3.2 Substrate Recognition Sites *82*
4.3.3 Structural Variability and Substrate Specificity Profiles *83*
4.3.3.1 CYP1A2 *83*
4.3.3.2 CYP2A6 *85*
4.3.3.3 CYP2C9 *85*
4.3.3.4 CYP2D6 *86*
4.3.3.5 CYP2E1 *87*
4.3.3.6 CYP3A4 *87*
4.4 Dynamics of CYPs *88*
4.4.1 Active Site Flexibility *88*
4.4.2 Active Site Solvation *93*
4.4.3 Active Site Access and Egress Pathways *93*
4.4.4 MD Simulations of CYPs in Lipid Bilayers *96*
4.5 Conclusions *96*
References *97*

5 Cytochrome P450 Substrate Recognition and Binding *103*
Andrew G. Leach and Nathan J. Kidley
5.1 Introduction *103*
5.2 Substrate Recognition in the Catalytic Cycle of CYPs *103*
5.3 Substrate Identity in Various Species *104*
5.4 Structural Insight into Substrate Recognition by CYPs *107*
5.4.1 CYP1A1, CYP1A2, and CYP1B1 *108*
5.4.2 CYP2A6 *108*
5.4.3 CYP2A13 *109*
5.4.4 CYP2C8 *110*
5.4.5 CYP2C9 *112*
5.4.6 CYP2D6 *112*
5.4.7 CYP2E1 *113*
5.4.8 CYP2R1 *113*
5.4.9 CYP3A4 *115*
5.4.10 CYP8A1 *115*
5.4.11 CYP11A1 *116*
5.4.12 CYP11B2 *118*
5.4.13 CYP19A1 *118*
5.4.14 CYP46A1 *119*
5.4.15 General Insights from Protein–Ligand Crystal Structures *119*
5.5 The Challenges of Using Docking for Predicting Kinetic Parameters *120*
5.6 Substrate Properties for Various Human Isoforms *120*
5.6.1 Kinetic Parameters K_m and k_{cat} and Their Relationship with Substrate and Protein Structure *124*
5.7 Conclusions *128*
References *128*

6 QM/MM Studies of Structure and Reactivity of Cytochrome P450 Enzymes: Methodology and Selected Applications *133*
Sason Shaik, Hui Chen, Dandamudi Usharani, and Walter Thiel
6.1 Introduction *133*
6.2 QM/MM Methods *135*
6.2.1 Methodological Issues in QM/MM Studies *136*
6.2.1.1 QM/MM Partitioning *136*
6.2.1.2 QM Methods *137*
6.2.1.3 MM Methods *138*
6.2.1.4 Subtractive versus Additive QM/MM Schemes *139*
6.2.1.5 Electrostatic QM/MM Interactions *139*
6.2.1.6 QM/MM Boundary Treatments *139*
6.2.1.7 QM/MM Geometry Optimization *140*
6.2.1.8 QM/MM Molecular Dynamics and Free Energy Calculations *140*
6.2.1.9 QM/MM Energy versus Free Energy Calculations *141*
6.2.2 Practical Issues in QM/MM Studies *141*
6.2.2.1 QM/MM Software *141*
6.2.2.2 QM/MM Setup *142*
6.2.2.3 Accuracy of QM/MM Results *143*
6.2.2.4 QM/MM Geometry Optimization *143*
6.2.2.5 Extracting Insights from QM/MM Calculations *144*
6.3 Selected QM/MM Applications to Cytochrome P450 Enzymes *144*
6.3.1 Formation of Cpd I from Cpd 0 *146*
6.3.1.1 Conversion of Cpd 0 into Cpd I in the T252X Mutants *148*
6.3.2 Properties of Cpd I *151*
6.3.2.1 Cpd I Species of Different Cytochrome P450s *154*
6.3.3 The Mechanism of Cytochrome P450 StaP *155*
6.3.4 The Mechanism of Dopamine Formation *160*
6.3.4.1 The Electrostatic Effect is Not Due to Simple Bulk Polarity *163*
6.4 An Overview of Cytochrome P450 Function Requires Reliable MD Calculations *163*
6.5 Conclusions *164*
References *165*

7 Computational Free Energy Methods for Ascertaining Ligand Interaction with Metabolizing Enzymes *179*
Mark J. Williamson
7.1 Introduction *179*
7.2 Linking Experiment and Simulation: Statistical Mechanics *180*
7.2.1 A Note on Chemical Transformations *182*
7.3 Taxonomy of Free Energy Methods *183*
7.3.1 Pathway Methods *183*
7.3.1.1 Pathway Planning: Using the State Nature of the Free Energy Cycle *184*
7.3.1.2 Free Energy Perturbation *185*

7.3.1.3 Bennett Acceptance Ratio *185*
7.3.1.4 Thermodynamic Integration *186*
7.3.2 Endpoint Methods *186*
7.3.2.1 Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) *186*
7.3.2.2 Linear Interaction Energy *187*
7.3.2.3 QM Endpoint Methods *187*
7.3.3 Summary of Free Energy Methods *187*
7.4 Ligand Parameterization *188*
7.5 Specific Examples *189*
7.5.1 Cytochrome P450 (CYP) *189*
7.5.2 Chorismate Mutase *192*
7.6 Conclusions *192*
References *193*

8 Experimental Approaches to Analysis of Reactions of Cytochrome P450 Enzymes *199*
Frederick Peter Guengerich
8.1 Introduction *199*
8.2 Structural Data and Substrate Binding *199*
8.3 Systems for Production of Reaction Products and Analysis of Systems *200*
8.3.1 *In Vivo* Systems *201*
8.3.2 Tissue Microsomal Systems *201*
8.3.3 Purified CYPs in Reconstituted Systems *201*
8.3.4 Membranes from Heterologous Expression Systems *202*
8.3.4.1 Mammalian Cells *202*
8.3.4.2 Insect Cell Systems (Using Baculovirus Infection for Expression) *202*
8.3.4.3 Microbial Membrane Systems *202*
8.4 Methods for Analysis of Products of Drugs *203*
8.4.1 Separation Methods *203*
8.4.1.1 High-Performance Liquid Chromatography *203*
8.4.1.2 Other Separation Methods *204*
8.4.2 Analysis Methods *204*
8.4.2.1 HPLC–UV *204*
8.4.2.2 LC–MS *205*
8.4.2.3 LC–MS/MS *205*
8.4.2.4 LC–HRMS *205*
8.4.2.5 NMR *205*
8.4.2.6 Other Spectroscopy of Metabolites *206*
8.5 Untargeted Searches for CYP Reactions *208*
8.6 Complex CYP Products *208*
8.7 Structure–Activity Relationships Based on Products *210*
8.7.1 SARs Based on Chemical Bond Energy *211*
8.7.2 SARs Based on Docking *211*

8.7.3 Knowledge-Based SAR *212*
8.8 SAR of Reaction Rates *213*
8.9 Other Issues in Predictions *213*
8.10 Conclusions *214*
References *214*

Part Four Computational Approaches to Study Sites and Products of Metabolism *221*

9 Molecular Interaction Fields for Predicting the Sites and Products of Metabolism *223*
Fabio Broccatelli and Nathan Brown
9.1 Introduction *223*
9.2 CYP from a GRID Perspective *224*
9.3 From Lead Optimization to Preclinical Phases: the Challenge of SoM Prediction *226*
9.3.1 MetaSite: Accessibility Function *227*
9.3.2 MetaSite: Reactivity Function *229*
9.3.3 MetaSite: Site of Metabolism Prediction *230*
9.3.4 MetaSite: Validation and Case Studies *231*
9.3.5 MetaSite: Prediction of CYP Inhibition *234*
9.3.6 MassMetaSite: Automated Metabolite Identification *236*
9.4 Conclusions *239*
References *241*

10 Structure-Based Methods for Predicting the Sites and Products of Metabolism *243*
Chris Oostenbrink
10.1 Introduction *243*
10.2 6 Å Rule *243*
10.3 Methodological Approaches *245*
10.4 Prediction of Binding Poses *247*
10.5 Protein Flexibility *249*
10.6 Role of Water Molecules *254*
10.7 Effect of Mutations *256*
10.8 Conclusions *258*
References *259*

11 Reactivity-Based Approaches and Machine Learning Methods for Predicting the Sites of Cytochrome P450-Mediated Metabolism *265*
Patrik Rydberg
11.1 Introduction *265*
11.2 Reactivity Models for CYP Reactions *268*

11.2.1 Hydroxylation of Aliphatic Carbon Atoms *268*
11.2.2 Hydroxylation and Epoxidation of Aromatic and Double Bonded Carbon Atoms *271*
11.2.3 Combined Carbon Atom Models *273*
11.2.4 Comprehensive Models *273*
11.3 Reactivity-Based Methods Applied to CYP-Mediated Site of Metabolism Prediction *274*
11.3.1 Methods Only Applicable to Carbon Atoms *274*
11.3.2 Comprehensive Methods *276*
11.4 Machine Learning Methods Applied to CYP-Mediated Site of Metabolism Prediction *278*
11.4.1 Atomic Descriptors *278*
11.4.2 Machine Learning Methods and Optimization Criteria *279*
11.5 Applications to SoM Prediction *280*
11.5.1 Isoform-Specific Models *281*
11.5.2 Isoform-Unspecific Models *283*
11.6 Combinations of Structure-Based Models and Reactivity *284*
11.7 Conclusions *285*
References *286*

12 Knowledge-Based Approaches for Predicting the Sites and Products of Metabolism *293*
Philip Neville Judson
12.1 Introduction *293*
12.2 Building and Maintaining a Knowledge Base *295*
12.3 Encoding Rules in a Knowledge Base *299*
12.4 Ways of Working with Rules *301*
12.5 Using the Logic of Argumentation *303*
12.6 Combining Absolute and Relative Reasoning *307*
12.7 Combining Predictions from Multiple Sources *310*
12.8 Validation and Assessment of Performance *312*
12.9 Conclusions *314*
References *314*

Part Five Computational Approaches to Study Enzyme Inhibition and Induction *319*

13 Quantitative Structure–Activity Relationship (QSAR) Methods for the Prediction of Substrates, Inhibitors, and Inducers of Metabolic Enzymes *321*
Oraphan Phuangsawai, Supa Hannongbua, and Mathew Paul Gleeson
13.1 Introduction *321*
13.2 *In Silico* QSAR Methods *322*
13.2.1 Experimental Variability *323*

13.2.2 Data Curation and Manipulation *324*
13.2.3 Molecular Descriptors *324*
13.2.4 Training SAR, QSAR, and Machine Learning Models *325*
13.2.5 Local versus Global QSAR Models *325*
13.2.6 SAR and Classical QSAR Methods *326*
13.2.7 Machine Learning QSAR Methods *327*
13.2.8 Model Assessment and Validation *327*
13.2.8.1 Assessing the Predictive Ability of QSAR Models *327*
13.2.8.2 Applicability Domains of QSAR Models *328*
13.3 QSAR Models for Cytochrome P450 *328*
13.3.1 Inhibition QSAR *328*
13.3.1.1 SAR *328*
13.3.1.2 Classical QSAR Models *329*
13.3.1.3 Machine Learning QSAR Models *333*
13.3.1.4 Classification Models *334*
13.3.1.5 3D QSAR Models *335*
13.3.2 Enzyme Induction QSAR *336*
13.4 Conjugative Metabolizing Enzymes *337*
13.4.1 Uridine Diphosphate Glucosyltransferase (UGT) QSAR *338*
13.4.2 Sulfotransferases QSAR *338*
13.5 *In Vitro* Clearance QSAR *339*
13.6 Conclusions *340*
References *341*

14 Pharmacophore-Based Methods for Predicting the Inhibition and Induction of Metabolic Enzymes *351*
Teresa Kaserer, Veronika Temml, and Daniela Schuster
14.1 Introduction *351*
14.2 Substrate and Inhibitor Pharmacophore Models *354*
14.2.1 Cytochrome P450 enzymes *354*
14.2.1.1 CYP1A2 *354*
14.2.1.2 CYP2B6 *355*
14.2.1.3 CYP2C9 *356*
14.2.1.4 CYP2C19 *357*
14.2.1.5 CYP2D6 *358*
14.2.1.6 CYP3A4 *359*
14.2.1.7 CYP3A5 and CYP3A7 *360*
14.2.2 UDP-Glucuronosyltransferases (UGTs) *361*
14.2.2.1 UGT1A1 *361*
14.2.2.2 UGT1A4 *361*
14.2.2.3 UGT1A9 *361*
14.2.2.4 UGT2B7 *362*
14.2.3 Interference with Recently Identified Phase I Metabolic Enzymes *362*
14.3 Inducer Models *363*
14.3.1 Hetero- and Autoactivation *363*

14.3.1.1 CYP2C9 *363*
14.3.1.2 CYP3A4 *364*
14.3.2 Nuclear Receptors *364*
14.3.2.1 Pregnane X Receptor *364*
14.3.2.2 CAR *366*
14.4 Conclusions *366*
References *368*

15 Prediction of Phosphoglycoprotein (*P-gp*)-Mediated Disposition in Early Drug Discovery *373*
Simon Thomas and Richard J. Dimelow
15.1 Introduction *373*
15.2 QSAR Modeling of Compounds Interacting with Transporters *376*
15.2.1 Experimental Data and Assays *376*
15.2.2 Descriptors Used in P-gp Substrate Identification *378*
15.2.3 QSAR Methods Used in P-gp Substrate Identification *380*
15.3 Influence of Compound Structure on P-gp Substrate Identity *380*
15.4 QSAR Models for P-gp Substrates *385*
15.5 Application to Drug Discovery *388*
15.6 Conclusions *391*
References *392*

16 Predicting Toxic Effects of Metabolites *397*
Andreas Bender
16.1 Introduction *397*
16.2 Methods for Predicting Toxic Effects *401*
16.2.1 Predicting Metabolites *401*
16.2.2 Predicting Relative and Absolute Metabolism Likelihoods and Rates *401*
16.2.3 Utilizing Pharmacogenetic Data to Anticipate Dose, Rate, and Time Information in an Individual Patient *402*
16.2.4 Predicting the Effect of the Resulting Metabolites *402*
16.2.4.1 Bioactivity-Based Mechanistic Models *403*
16.2.4.2 Incorporating Pathway Information into Toxicity Models *404*
16.2.4.3 Toxicogenetic and Pharmacogenomic Approaches *406*
16.2.4.4 Knowledge-Based Systems *407*
16.2.4.5 Reactive Metabolites *407*
16.2.5 Current Scientific and Political Developments Regarding Metabolism and Toxicity Prediction *408*
16.3 Conclusions *408*
References *409*

Part Six Experimental Approaches to Study Metabolism *413*

17 *In Vitro* Models for Metabolism: Applicability for Research on Food Bioactives *415*
Natalie D. Glube and Guus Duchateau
17.1 Introduction *415*
17.1.1 Bioavailability *416*
17.1.2 Intestinal Absorption *416*
17.1.3 First-Pass Metabolism *418*
17.2 Classification of *In Vitro* Models for Metabolism *418*
17.3 Modifications via Gut (Colon) Microflora *419*
17.3.1 Background Information *419*
17.3.2 *In Vitro* Models *420*
17.3.2.1 Fecal Slurry *421*
17.3.2.2 Isolated Pure Bacterial Cultures *421*
17.3.2.3 Complex Intestinal Models (TIM-2) *421*
17.4 Intestinal (Gut Wall) Metabolism *421*
17.4.1 Background Information *421*
17.4.2 *In Vitro* Models *422*
17.4.2.1 Tissue Intact Models *423*
17.4.2.2 Subcellular and Cellular Models *423*
17.5 Hepatic Metabolism *423*
17.5.1 Background Information *423*
17.5.2 *In Vitro* Models *424*
17.5.2.1 Supersomes: Recombinant Phase I and Phase II Enzymes *424*
17.5.2.2 Microsomes *424*
17.5.2.3 S9 Fractions *426*
17.5.2.4 Hepatocyte Cell Lines *426*
17.5.2.5 Primary Cultures: Cryopreserved Hepatocytes *427*
17.5.2.6 Cryopreserved Hepatocytes versus Microsomes *428*
17.5.2.7 Hepatocytes in Culture *429*
17.6 Pharmacokinetic Data Obtainable from *In Vitro* Metabolism Models *431*
17.6.1 Pharmacokinetic Analysis *431*
17.6.1.1 Measurement Methodology: Substrate Depletion versus Metabolite Formation *432*
17.6.1.2 Mathematical Models for Metabolism: Well-Stirred, Parallel Tube, and Dispersion Models *432*
17.7 Assay Validation *433*
17.7.1 Selection and Preparation of Reference Compounds *433*
17.7.2 Analytics *434*
17.7.3 Theoretical Steps to Establish an *In Vitro* Model *434*
17.8 Conclusions *435*
17.8.1 What Can We Summarize from the Literature? *435*

17.8.2 What Questions We Wish to Have Answered Will Determine Which Model We Select *436*
References *438*

18 *In Vitro* Approaches to Study Drug–Drug Interactions *441*
Stephen S. Ferguson and Jessica A. Bonzo
18.1 Introduction *441*
18.1.1 Additional Factors Influencing Drug Metabolism *442*
18.2 Inhibition of Drug Metabolism *444*
18.2.1 *In Vitro* Models for Predicting Inhibition of Drug Metabolism *444*
18.2.1.1 Human Liver Microsomes *445*
18.2.1.2 S9 and Cytosol *456*
18.2.1.3 Recombinant Enzymes *457*
18.2.1.4 Primary Hepatocytes *458*
18.3 Transcriptional Regulation of Metabolism *460*
18.3.1 Gene Induction Pathways *460*
18.3.2 Gene Repression/Suppression *462*
18.3.3 *In Vitro* Models for Predicting Induction of Drug Metabolism Enzymes *463*
18.3.3.1 Ligand Binding Assays *463*
18.3.3.2 Gene Reporter Assays *465*
18.3.3.3 Cellular Models for Induction Studies *466*
18.3.3.4 Induction Assays in Cellular Models *468*
18.3.3.5 Treatment with Control and Test Compounds *470*
18.3.3.6 Gene Expression in Cellular Models for Induction *471*
18.3.3.7 Enzymatic Activity in Metabolically Competent Cellular Models of Induction *474*
18.4 Next-Generation Models and Concluding Remarks *474*
References *477*

19 Metabolite Detection and Profiling *485*
Ian D. Wilson
19.1 Introduction *485*
19.2 Chromatography *486*
19.3 Mass Spectrometry *487*
19.4 Sample Preparation for LC–MS-Based Metabolite Profiling *490*
19.5 Metabolic Profiling by LC–MS *491*
19.5.1 Metabolic Stability and Cytochrome P450 Inhibition Assays *491*
19.5.2 Metabolite Profiling, Detection, and Identification from *In Vivo* and *In Vitro* Studies *492*
19.5.3 Reactive Metabolite Detection *496*
19.6 Conclusions *496*
References *497*

Index *499*